Skip to main content

Table 3 Clinical response in 17 evaluable patients

From: Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

  No. (%) Clinical benefit Median OS (months)
PR 1 (5.8) 7/17 (41%) 14
SD 6 (35.2)
PD 10 (58.8)   6.5
All 17 patients    10
  1. PR Partial response, SD Stable disease, PD Progressive disease, OS Overall survival.